LSL Pharma Group Inc. LSL.V
TSX
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | 17.87% | 70.65% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 17.87% | 70.65% | |||
| Cost of Revenue | 10.70% | 67.41% | |||
| Gross Profit | 125.28% | 140.50% | |||
| SG&A Expenses | -5.18% | 4.40% | |||
| Depreciation & Amortization | 418.30% | 120.97% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 10.29% | 58.80% | |||
| Operating Income | 40.48% | -8.36% | |||
| Income Before Tax | 21.12% | -146.58% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 21.12% | -161.19% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 21.12% | -161.19% | |||
| EBIT | 40.48% | -8.36% | |||
| EBITDA | 97.37% | 33.96% | |||
| EPS Basic | 20.99% | -149.23% | |||
| Normalized Basic EPS | 20.79% | -8.60% | |||
| EPS Diluted | 11.11% | -149.23% | |||
| Normalized Diluted EPS | 20.79% | -8.60% | |||
| Average Basic Shares Outstanding | 0.00% | 4.04% | |||
| Average Diluted Shares Outstanding | -0.05% | 4.10% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||